ES2166097T3 - Glicoconjugados de neisseria meningitidis de serogrupo b y procedimientos para usarlos. - Google Patents

Glicoconjugados de neisseria meningitidis de serogrupo b y procedimientos para usarlos.

Info

Publication number
ES2166097T3
ES2166097T3 ES97936364T ES97936364T ES2166097T3 ES 2166097 T3 ES2166097 T3 ES 2166097T3 ES 97936364 T ES97936364 T ES 97936364T ES 97936364 T ES97936364 T ES 97936364T ES 2166097 T3 ES2166097 T3 ES 2166097T3
Authority
ES
Spain
Prior art keywords
glycoconjugates
neisseria meningitidis
neisseria
vaccine formulations
serogrupo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97936364T
Other languages
English (en)
Other versions
ES2166097T5 (es
Inventor
Robert C Seid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21820678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2166097(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of ES2166097T3 publication Critical patent/ES2166097T3/es
Application granted granted Critical
Publication of ES2166097T5 publication Critical patent/ES2166097T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/917—Vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE EN GENERAL A NUEVOS GLUCOCONJUGADOS DEL GRUPO SEROLOGICO B DE LA NEISSERIA MENINGITIDIS. MAS CONCRETAMENTE, LA INVENCION PERTENECE A GLUCOCONJUGADOS FORMADOS A PARTIR DE UN DERIVADO DE OLISACARIDO CAPSULAR DEL SEROGRUPO B DE LA NEISSERIA MENINGITIDIS (DERIVADO MENBOS) EN EL QUE GRUPOS N - ACETILO DEL RESIDUO DE ACIDO SIALICO SON SUSTITUIDOS POR GRUPOS N - ACILO. LA INVENCION SE REFIERE IGUALMENTE A FORMULACIONES DE VACUNAS QUE CONTIENEN LOS GLUCOCONJUGADOS, PROCEDIMIENTOS PARA REALIZAR LAS FORMULACIONES DE VACUNAS Y PROCEDIMIENTOS PARA EL USO DE DICHAS FORMULACIONES PARA EL TRATAMIENTO O PREVENCION DE LA ENFERMEDAD PRODUCIDA POR EL GRUPO SEROLOGICO B DE LA NEISSERIA MENINGITIDIS O DE LA E. COLI K1, EN UN SUJETO MAMIFERO.
ES97936364T 1996-08-27 1997-08-04 Glicoconjugados de neisseria meningitidis de serogrupo b y procedimientos para usarlos. Expired - Lifetime ES2166097T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2445496P 1996-08-27 1996-08-27
US24454P 1996-08-27

Publications (2)

Publication Number Publication Date
ES2166097T3 true ES2166097T3 (es) 2002-04-01
ES2166097T5 ES2166097T5 (es) 2007-03-16

Family

ID=21820678

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97936364T Expired - Lifetime ES2166097T5 (es) 1996-08-27 1997-08-04 Glicoconjugados de neisseria meningitidis de serogrupo b y procedimientos para usarlos.

Country Status (10)

Country Link
US (2) US6638513B2 (es)
EP (1) EP0939647B2 (es)
JP (2) JP4162267B2 (es)
AT (1) ATE208629T1 (es)
CA (1) CA2264735C (es)
DE (1) DE69708318T3 (es)
DK (1) DK0939647T4 (es)
ES (1) ES2166097T5 (es)
PT (1) PT939647E (es)
WO (1) WO1998008543A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0922059B1 (en) 1996-08-27 2003-10-22 Chiron Corporation Monoclonal antibodies that define unique meningococcal b epitopes and their use in the preparation of vaccine compositions
JP4162267B2 (ja) * 1996-08-27 2008-10-08 カイロン コーポレイション Ｎｅｉｓｓｅｒｉａ ｍｅｎｉｎｇｉｔｉｄｉｓ血清型Ｂ複合糖質およびその使用法
EP0994723A1 (en) 1997-06-24 2000-04-26 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
GB9808866D0 (en) * 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
ES2278446T3 (es) * 1998-05-29 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Vacunas combinadas b/c contra la meningitis.
WO2002080648A2 (en) * 2001-04-05 2002-10-17 Chiron Corporation Mucosal boosting following parenteral priming
RU2322451C2 (ru) 2001-04-17 2008-04-20 Новартис Вэксинс Энд Диагностикс, Инк. Молекулярные миметики эпитопов менингококка в, которые вызывают выработку функционально активных антител
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
WO2003080678A1 (en) * 2002-03-26 2003-10-02 Chiron Srl Modified saccharides having improved stability in water
DK1587537T3 (da) 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
US8148335B2 (en) 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
WO2006002402A2 (en) * 2004-06-23 2006-01-05 Children's Hospital & Research Center At Oakland Polysaccharide derivatives and uses in induction of an immune response
GB0611914D0 (en) * 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
JP5523313B2 (ja) 2007-07-03 2014-06-18 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド ポリシアル酸誘導体、製造方法、ならびにがん抗原産生の増強およびターゲティングにおける使用
JP5702600B2 (ja) * 2007-07-03 2015-04-15 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド オリゴシアル酸誘導体、製造方法および免疫学的使用
AU2011288203A1 (en) * 2010-03-18 2012-08-23 Novartis Ag Adjuvanted vaccines for serogroup B meningococcus
PL3831406T3 (pl) 2010-08-23 2024-09-09 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
RU2546873C2 (ru) 2010-09-10 2015-04-10 УАЙТ ЭлЭлСи Нелипидизированные варианты антигенов neisseria meningitidis orf2086
PL2726511T3 (pl) 2011-07-01 2019-12-31 Ngm Biopharmaceuticals, Inc. Kompozycje, zastosowania i sposoby leczenia zaburzeń oraz chorób metabolicznych
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY167723A (en) 2012-03-09 2018-09-21 Pfizer Neisseria meningitidis compositions and methods thereof
WO2014014821A1 (en) 2012-07-19 2014-01-23 Redwood Biosciences, Inc. Antibody specific for cd22 and methods of use thereof
SI2885010T1 (sl) 2012-08-16 2020-07-31 Ipierian, Inc. Metode zdravljenja tauopatije
CN104870475B (zh) 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
CA2889197A1 (en) 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
EP3798228A1 (en) 2012-11-28 2021-03-31 NGM Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
KR101980989B1 (ko) * 2012-12-20 2019-05-21 화이자 인코포레이티드 당접합 방법
SG11201504815QA (en) 2012-12-27 2015-07-30 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
EA039554B1 (ru) 2013-06-10 2022-02-09 АйПИЕРИАН, ИНК. Способ снижения уровней a40 и/или a42 в нервной клетке и/или во внеклеточной жидкости
EP4098276A1 (en) 2013-09-08 2022-12-07 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2015081085A2 (en) 2013-11-27 2015-06-04 Ipierian, Inc. Methods of treating a tauopathy
CN114129709A (zh) 2014-10-23 2022-03-04 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CA3003616C (en) 2015-11-09 2020-07-28 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
US10934347B2 (en) 2016-04-04 2021-03-02 Genzyme Corporation Anti-complement factor BB antibodies and uses thereof
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902506A (en) † 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4727136A (en) † 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
NZ223009A (en) * 1986-12-31 1990-06-26 Nl Rivm Of Thoven Oligosaccharides containing d-ribose d-ribitol and phosphate units mimicing haemophilus influenzae type b antigens
WO1991008772A1 (en) 1989-12-14 1991-06-27 National Research Council Of Canada Improved meningococcal polysaccharide conjugate vaccine
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5354853A (en) * 1993-03-12 1994-10-11 Genzyme Corporation Phospholipid-saccharide conjugates
GB9422096D0 (en) 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
WO1996040225A1 (en) * 1995-06-07 1996-12-19 Alberta Research Council Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them
JP4162267B2 (ja) * 1996-08-27 2008-10-08 カイロン コーポレイション Ｎｅｉｓｓｅｒｉａ ｍｅｎｉｎｇｉｔｉｄｉｓ血清型Ｂ複合糖質およびその使用法
EP0922059B1 (en) 1996-08-27 2003-10-22 Chiron Corporation Monoclonal antibodies that define unique meningococcal b epitopes and their use in the preparation of vaccine compositions
EP0994723A1 (en) * 1997-06-24 2000-04-26 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
PT1630168E (pt) 1997-08-27 2011-07-20 Novartis Vaccines & Diagnostic Compostos miméticos moleculares de péptidos de meningococos do serogrupo b

Also Published As

Publication number Publication date
WO1998008543A1 (en) 1998-03-05
US20020034518A1 (en) 2002-03-21
EP0939647A1 (en) 1999-09-08
US6638513B2 (en) 2003-10-28
US7169392B2 (en) 2007-01-30
DE69708318T3 (de) 2006-11-16
CA2264735C (en) 2008-01-29
ATE208629T1 (de) 2001-11-15
DK0939647T4 (da) 2006-10-23
DE69708318T2 (de) 2002-07-11
JP4162267B2 (ja) 2008-10-08
DE69708318D1 (de) 2002-01-03
EP0939647B2 (en) 2006-07-12
DK0939647T3 (da) 2002-04-02
CA2264735A1 (en) 1998-03-05
EP0939647B1 (en) 2001-11-14
JP2008201793A (ja) 2008-09-04
US20040052805A1 (en) 2004-03-18
HK1021145A1 (en) 2000-06-02
ES2166097T5 (es) 2007-03-16
PT939647E (pt) 2002-04-29
JP2001500540A (ja) 2001-01-16

Similar Documents

Publication Publication Date Title
ES2166097T3 (es) Glicoconjugados de neisseria meningitidis de serogrupo b y procedimientos para usarlos.
YU24391A (sh) Poboljšana meningokokna polisaharid kon-jugovana vakcina
CY1109202T1 (el) Συνθεσεις που περιεχουν αντιγονα απο τους οροτυπους b και c της neisseria meningitidis οπως και επιπλεον αντιγονα απο τον οροτυπο α
ATE505478T1 (de) Molekular-mimetika von meningokokkalen b epitopen
BR9910749A (pt) Composições e vacinas imunogênicas combinadas para meningites b e c e método de induzir uma resposta imune por administração da mesma
ITFI920058A1 (it) Composti coniugati formati da proteine heat shock (hsp) e oligo-polisaccaridi, loro uso per la produzione di vaccini.
NO930601D0 (no) Heterocykliske forbindelser og deres fremstilling og anvendelse
NO912369D0 (no) Meningokokk-klasse-1-ytre-membranvaksine.
ES2119836T3 (es) Aparato para aplicar sujetadores quirurgicos.
BR9611533A (pt) Lipopoliamina composição e utilização e processo de preparação de uma lipopoliamina
WO2001006984A3 (en) Small molecules useful in the treatment of inflammatory disease
DK0749429T3 (da) 3,5-Disubstituerede og 3,4,5-trisubstituerede 2-isoxazoliner og isoxazoler, fremgangsmåder til deres fremstilling og deres
NO972391D0 (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
TR200101962T2 (tr) Sindirim sistemi bozukluklarını tedavi etmek için 4-(aminometil)-piperidin benzamidler
PT979079E (pt) Utilizacao de derivados da tetra-hidropiridina para a preparacao de medicamentospara o tratamento das doencas que provocam uma desmielinizacao
DE58902712D1 (de) N-acetylglucosamin-zubereitungen zur buccalen anwendung.
ATE277907T1 (de) Blutzuckersenkende und lipidsenkende verbindungen
MX9300205A (es) Compuestos policiclicos disubstituidos y composicion farmaceutica que los contiene.
SE9400524L (sv) Energipreparat
AR041116A1 (es) Metodos para tratar pacientes que sufen el sindrome de piernas inquietas o desordenes relacionados
EE04040B1 (et) Aminotetraliini derivaat kardiovaskulaarsete haiguste raviks
BRPI0412506A (pt) células autólogas que induzem à autotoleráncia de origem monocìtica e seu uso em preparações farmacêuticos
DK0744951T3 (da) Fremgangsmåde til fremstilling af en steril prednisolongen
DK598184A (da) 3-aryl-1,2-benzisoxazolsulfonyl- og -sulfinylalkansyrer og farmaceutisk acceptable salte deraf, deres fremstilling og anvendelse som laegemidler
PT1535928E (pt) Composições de vacina compreendendo proteínas omp85 de neisseria gonorrhoeae e neisseria meningitidis

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 939647

Country of ref document: ES